scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1048060148 |
P356 | DOI | 10.1385/MO:19:2:79 |
P698 | PubMed publication ID | 12180484 |
P50 | author | Jan Palmblad | Q65768736 |
P2093 | author name string | J Westin | |
M Björkholm | |||
B Markevärn | |||
J Kutti | |||
M Merup | |||
N Mauritzson | |||
C Maim | |||
G Birgergård | |||
Swedish National Study Group on Chronic Myeloproliferative Disorders | |||
P2860 | cites work | Thalidomide is an inhibitor of angiogenesis | Q24563363 |
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. | Q33338281 | ||
Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines | Q33773400 | ||
Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 | ||
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. | Q34503538 | ||
Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity | Q35745897 | ||
Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia | Q41114232 | ||
Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders | Q41618119 | ||
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | Q42547622 | ||
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma | Q43503967 | ||
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. | Q43700135 | ||
Thalidomide in agnogenic and secondary myelofibrosis | Q43795704 | ||
Reversal of myelofibrosis by hydroxyurea | Q44986162 | ||
Life expectancy of patients with chronic nonleukemic myeloproliferative disorders | Q70138586 | ||
Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia | Q73458297 | ||
P433 | issue | 2 | |
P921 | main subject | thalidomide | Q203174 |
myelofibrosis | Q1752571 | ||
P304 | page(s) | 79-86 | |
P577 | publication date | 2002-01-01 | |
P1433 | published in | Medical Oncology | Q2152666 |
P1476 | title | Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia | |
P478 | volume | 19 |
Q50477923 | Ex vivo activity of thalidomide in childhood acute leukemia. |
Q93085740 | Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019 |
Q39244371 | How I treat splenomegaly in myelofibrosis |
Q35964242 | New approaches in the treatment of myelofibrosis |
Q33389330 | New drugs for the treatment of myelofibrosis |
Q36157668 | Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study |
Q36604028 | Ruxolitinib for myelofibrosis |
Q42090824 | Ruxolitinib for the treatment of myelofibrosis: its clinical potential |
Q33359542 | Thalidomide for the treatment of idiopathic myelofibrosis |
Q83049404 | Thalidomide therapy for myelofibrosis with myeloid metaplasia |
Q37860336 | Therapeutic approaches in myelofibrosis. |
Search more.